Mirum Pharmaceuticals' promising pipeline and strong financials make it an attractive buy in the competitive PBC space. Click ...

The Company also announced the discontinuation of the development of its drug INCB000547 for patients with cholestatic pruritus (CP). Both of these drugs stem from Incyte's $750 million acquisition of ...

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte ...

Linerixibat is a small molecule commercialized by GSK, with a leading Phase III program in Pruritus. According to Globaldata, it is involved in 15 clinical trials, of which 12 were completed, and 3 ...

(Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum’s Board of Directors granted ...

It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally.

在 Cell 子刊 Cell Host & Microbe 上发表了题为Zinc promotes microbial p-coumaric acid production that protects against cholestatic liver injury 的研究论文。 该研究揭示了锌与 ...

The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor ...

The company’s lead product is Livmarli (maralixibat), an orally administered ileal bile acid transporter (“IBAT”) inhibitor approved for the treatment of cholestatic pruritus in patients ...